カテゴリ： Allied Market Research, 世界, 医療/バイオ

群発頭痛のグローバル市場（2021～2031）：反復発作性、慢性

■ 英語タイトル：Cluster Headache Market By Type (Episodic, Chronic), By Drug class (Ergot derivatives, Calcium channel blockers, Triptans, Others), By Distribution channel (Hospital pharmacies, Drug stores and retail pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23MC096）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23MC096
■ 発行日：2023年1月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：233
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[群発頭痛のグローバル市場（2021～2031）：反復発作性、慢性]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の調査資料では、2021年には356.00百万ドルであった世界の群発頭痛市場規模が2031年には522.98百万ドルへ及び、2022年から2031年の間にCAGR 3.9％増加すると推測されています。本調査資料では、群発頭痛の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、種類別（反復発作性、慢性）分析、薬剤クラス別（麦角誘導体、カルシウム拮抗剤、トリプタン、その他）分析、流通チャネル別（病院内薬局、ドラッグストア・小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などを整理しました。並びに、本資料に記載されている企業として、Dr. Reddy’s Laboratories Ltd.、FRESENIUS SE & Co. KGaA (Fresenius Kabi)、GlaxoSmithKline plc、Pfizer Inc.、Teva Pharmaceutical Industries Ltd.、Arrotex Australia Group、Grunenthal、Eli Lilly and Company、Novartis AG、Sun Pharmaceutical Industries Ltd.などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の群発頭痛市場規模：種類別
- 反復発作性群発頭痛の市場規模
- 慢性群発頭痛の市場規模
・世界の群発頭痛市場規模：薬剤クラス別
- 麦角誘導体の市場規模
- カルシウム拮抗剤の市場規模
- トリプタンの市場規模
- その他薬剤の市場規模
・世界の群発頭痛市場規模：流通チャネル別
- 病院内薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンラインプロバイダーチャネルの市場規模
・世界の群発頭痛市場規模：地域別
- 北米の群発頭痛市場規模
- ヨーロッパの群発頭痛市場規模
- アジア太平洋の群発頭痛市場規模
- 中南米/中東・アフリカの群発頭痛市場規模
・競争状況
・企業情報

群発頭痛の市場規模は2021年に3億5,600万ドル、2031年には5億2,298万ドルに達すると推定され、2022年から2031年までの年平均成長率は3.9%となる見込みです。

群発頭痛は、三叉神経自律神経セファルジア（TAC）として知られる一次性頭痛の最も一般的なタイプです。群発頭痛は、15～180分続く非常に激しい片側性の頭痛発作が特徴で、1日に数回起こることもあります。痛みの激しさ、発作の長さ、流涙や結膜充血などの頭部自律神経症状の有無によって区別されます。発作はしばしば群発し、一度に数週間から数ヵ月にわたって連続して起こり、その後、完全寛解期を迎えます。この重大な痛みは、群発頭痛の期間中、特に自殺傾向の増加を伴います。

群発頭痛市場の推進要因は、群発頭痛に罹患する患者数の増加、群発頭痛に有効な治療薬の開発に向けた投資の増加です。 また、群発頭痛などの神経疾患の罹患率の急増により、頭痛疾患の治療に有効な薬剤の需要が高まっているため、群発頭痛の罹患率の増加が市場の成長を促進すると予想されます。例えば、SAGE Journal – Cephalgia 2022に掲載された論文によると、ノルウェーにおける群発頭痛の有病率は10万人あたり48.6人/年であることが判明しており、市場の成長を牽引しています。また、群発頭痛を治療するためのパイプライン医薬品の数が増加しており、今後数年間で規制当局の承認を受けると予想されることから、市場の拡大が促進されると予測されています。

さらに、群発頭痛のような頭痛疾患に関わる研究開発活動に対して、政府や民間機関からさまざまな助成金や奨学金が提供されており、これが市場拡大をさらに後押ししています。例えば、国際頭痛学会（IHS）の報告書（2022年）によると、IHSは、若手研究者の革新的でインパクトのある研究を支援し、頭痛分野における若手研究者のキャリアを促進し、頭痛疾患の知識基盤を増やすために、「IHSジュニア研究助成金」など合計20～30件のフェローシップを提供しており、頭痛疾患の研究開発のためのこのような利用可能なフェローシップは、市場の成長を促進すると予想されています。

しかし、医薬品の承認手続きに時間がかかり、規制当局が厳しいことが市場の成長を抑制する要因となっています。さらに、有利な償還政策がないことも、市場の成長を抑制すると予想されます。

さらに、生物学的製剤のような新規治療薬に対する需要の増加、治療選択肢に対する意識の高まり、群発頭痛治療のための安全で有効な薬剤を開発するための研究開発の増加は、群発頭痛市場の主要プレイヤーに有利な機会を提供します。

群発頭痛市場は、種類、薬剤クラス、流通チャネル、地域に区分されます。
種類別では、市場は反復性と慢性に分類されます。
薬剤クラス別では、エルゴ誘導体、カルシウム拮抗薬、トリプタン系薬剤、その他に分類されます。
流通チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア、小売薬局に分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）に市場を分けて分析しています。

世界の群発頭痛市場で事業を展開する主な主要企業は、Arrotex Australia Group、AstraZeneca、Dr. Reddy’s Laboratories Ltd.、Eli Lilly and Company、Fresenius SE & Co. KGaA、GlaxoSmithKline plc、Novartis AG、Pfizer Inc.、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd.などです。

〈ステークホルダーにとっての主なメリット〉
・2021年から2031年までの群発頭痛市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、群発頭痛の市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・群発頭痛市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界別の群発頭痛の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を収録しています。

〈主要市場セグメント〉
薬剤クラス別
エルゴ誘導体
カルシウム拮抗薬
トリプタン系薬剤
その他

流通チャネル別
病院薬局
ドラッグストア・小売薬局
その他

種類別
反復性
慢性

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Dr. Reddy’s Laboratories Ltd.
FRESENIUS SE & Co. KGaA (Fresenius Kabi)
GlaxoSmithKline plc
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Arrotex Australia Group
Grunenthal
Eli Lilly and Company
Novartis AG
Sun Pharmaceutical Industries Ltd.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cluster headache
3.4.1.2. Development of novel therapeutics for treatment of cluster headache
3.4.1.3. Increase in awareness about cluster headache

3.4.2. Restraints
3.4.2.1. Side effects associated with medications used for cluster headache

3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CLUSTER HEADACHE MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Episodic
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chronic
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: CLUSTER HEADACHE MARKET, BY DRUG CLASS
5.1. Overview
5.1.1. Market size and forecast
5.2. Ergot derivatives
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Calcium channel blockers
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Triptans
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: CLUSTER HEADACHE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Drug class
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Drug class
7.2.5.1.4. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Drug class
7.2.5.2.4. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Drug class
7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Drug class
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Drug class
7.3.5.1.4. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Drug class
7.3.5.2.4. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Drug class
7.3.5.3.4. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Drug class
7.3.5.4.4. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Drug class
7.3.5.5.4. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Drug class
7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Drug class
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Drug class
7.4.5.1.4. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Drug class
7.4.5.2.4. Market size and forecast, by Distribution channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Drug class
7.4.5.3.4. Market size and forecast, by Distribution channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Drug class
7.4.5.4.4. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Type
7.4.5.5.3. Market size and forecast, by Drug class
7.4.5.5.4. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Type
7.4.5.6.3. Market size and forecast, by Drug class
7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Drug class
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Drug class
7.5.5.1.4. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Drug class
7.5.5.2.4. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Type
7.5.5.3.3. Market size and forecast, by Drug class
7.5.5.3.4. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Type
7.5.5.4.3. Market size and forecast, by Drug class
7.5.5.4.4. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Dr. Reddy’s Laboratories Ltd.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Eli Lilly and Company
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. GlaxoSmithKline plc
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Novartis AG
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Pfizer Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Teva Pharmaceutical Industries Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Arrotex Australia Group
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Key strategic moves and developments
9.10. Grunenthal
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. CLUSTER HEADACHE MARKET FOR EPISODIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. CLUSTER HEADACHE MARKET FOR CHRONIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. GLOBAL CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 05. CLUSTER HEADACHE MARKET FOR ERGOT DERIVATIVES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 06. CLUSTER HEADACHE MARKET FOR CALCIUM CHANNEL BLOCKERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. CLUSTER HEADACHE MARKET FOR TRIPTANS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. CLUSTER HEADACHE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. GLOBAL CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 10. CLUSTER HEADACHE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. CLUSTER HEADACHE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. CLUSTER HEADACHE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. CLUSTER HEADACHE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NORTH AMERICA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. U.S. CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. U.S. CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 20. U.S. CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 21. CANADA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANADA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 23. CANADA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 26. MEXICO CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 29. EUROPE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 30. EUROPE CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GERMANY CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GERMANY CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 33. GERMANY CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 34. FRANCE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. FRANCE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 36. FRANCE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 37. UK CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. UK CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 39. UK CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 40. ITALY CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. ITALY CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 42. ITALY CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 43. SPAIN CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. SPAIN CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 45. SPAIN CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 46. REST OF EUROPE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. REST OF EUROPE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 48. REST OF EUROPE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 53. JAPAN CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. JAPAN CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 55. JAPAN CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. CHINA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. CHINA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 58. CHINA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 59. INDIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. INDIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 62. AUSTRALIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 63. AUSTRALIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 64. AUSTRALIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 65. SOUTH KOREA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. SOUTH KOREA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 67. SOUTH KOREA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 68. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 70. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 71. LAMEA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LAMEA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 73. LAMEA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 74. LAMEA CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 75. BRAZIL CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 76. BRAZIL CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 77. BRAZIL CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 84. REST OF LAMEA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. REST OF LAMEA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 86. REST OF LAMEA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 87. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
TABLE 88. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 89. DR. REDDY’S LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 90. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 91. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 92. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 93. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 94. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 95. ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 96. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): KEY EXECUTIVES
TABLE 97. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): COMPANY SNAPSHOT
TABLE 98. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT SEGMENTS
TABLE 99. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT PORTFOLIO
TABLE 100. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 101. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 102. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 103. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 104. NOVARTIS AG: KEY EXECUTIVES
TABLE 105. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 106. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 107. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 108. PFIZER INC.: KEY EXECUTIVES
TABLE 109. PFIZER INC.: COMPANY SNAPSHOT
TABLE 110. PFIZER INC.: PRODUCT SEGMENTS
TABLE 111. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 120. ARROTEX AUSTRALIA GROUP: KEY EXECUTIVES
TABLE 121. ARROTEX AUSTRALIA GROUP: COMPANY SNAPSHOT
TABLE 122. ARROTEX AUSTRALIA GROUP: PRODUCT SEGMENTS
TABLE 123. ARROTEX AUSTRALIA GROUP: PRODUCT PORTFOLIO
TABLE 124. ARROTEX AUSTRALIA GROUP: KEY STRATERGIES
TABLE 125. GRUNENTHAL: KEY EXECUTIVES
TABLE 126. GRUNENTHAL: COMPANY SNAPSHOT
TABLE 127. GRUNENTHAL: PRODUCT SEGMENTS
TABLE 128. GRUNENTHAL: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗コクシジウム薬のグローバル市場（2021〜2031）：イオノフォア、合成薬
  • 治療薬物モニタリング（TDM）のグローバル市場（2021-2031）：消耗品、装置
  • 経口抗ウィルス薬のグローバル市場（2021-2031）：肝炎、ヒト免疫不全ウイルス（HIV）、インフルエンザ、その他
  • 坐骨神経痛治療のグローバル市場（2021～2031）：急性坐骨神経痛、慢性坐骨神経痛、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23MC096 )"群発頭痛のグローバル市場（2021～2031）：反復発作性、慢性" (英文：Cluster Headache Market By Type (Episodic, Chronic), By Drug class (Ergot derivatives, Calcium channel blockers, Triptans, Others), By Distribution channel (Hospital pharmacies, Drug stores and retail pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。